[1] |
World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern[EB/OL]. (2021-11-26)[2022-03-23].
URL
|
[2] |
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study[J]. BMJ,2022,376:1-12.
|
[3] |
中华人民共和国国家卫生健康委员会办公厅,中华人民共和国国家中医药管理局综合司. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中国医药,2023,18(2):161-166.
|
[4] |
World Health Organization. Tracking SARS-CoV-2 variants[EB/OL]. (2023-06-19)[2022-03-23].
URL
|
[5] |
Lazarevic I, Pravica V, Miljanovic D, et al. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?[J]. Viruses,2021,13(7):1-17.
|
[6] |
中国疾病预防控制中心. 全国新型冠状病毒感染疫情情况[EB/OL]. (2023-02-01)[2022-03-23].
URL
|
[7] |
Magnus MC, Oakley L, Gjessing HK, et al. Pregnancy and risk of COVID-19: a Norwegian registry-linkage study[J]. BJOG,2022,129(1):101-109.
|
[8] |
Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22-October 3, 2020[J]. Morbidity and Mortality Weekly Report,2020,69(44):1641-1647.
|
[9] |
McClymont E, Albert AY, Alton GD, et al. Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes[J]. JAMA,2022,327(20):1983-1991.
|
[10] |
Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics[J]. Eur Rev Med Pharmacol Sci,2021,25(24):8012-8018.
|
[11] |
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study[J]. Lancet,2022,399(10335):1618-1624.
|
[12] |
Adhikari EH, MacDonald L, SoRelle JA, et al. COVID-19 cases and disease severity in pregnancy and neonatal positivity associated with delta (B. 1.617. 2) and omicron (B. 1.1. 529) variant predominance[J]. JAMA,2022,327(15):1500-1502.
|
[13] |
Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020-January 2022[J]. Morbidity and Mortality Weekly Report,2022,71(4):146-152.
|
[14] |
Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study[J]. Lancet,2022,400(10350):452-461.
|
[15] |
Edwards MJ. Hyperthermia and fever during pregnancy[J]. Birth Defects Res A Clin Mol Teratol,2006,76(7):507-516.
|
[16] |
Dreier JW, Andersen A-MN, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring[J]. Pediatrics,2014,133(3):e674-e688.
|
[17] |
Chambers CD, Johnson KA, Dick LM, et al. Maternal fever and birth outcome: a prospective study[J]. Teratology,1998,58(6):251-257.
|
[18] |
Sass L, Urhoj S, Kjærgaard J, et al. Fever in pregnancy and the risk of congenital malformations: a cohort study[J]. BMC Pregnancy Childbirth,2017,17(1):1-9.
|
[19] |
张露,杨菁,魏敏,等. 妊娠不同时期感染新型冠状病毒肺炎的随访研究[J]. 现代妇产科进展,2022,31(1):15-20,28.
|
[20] |
Serra FE, Rosa Junior ER, de Rossi P, et al. COVID-19: impact of original, Gamma, Delta, and Omicron variants of SARS-CoV-2 in vaccinated and unvaccinated pregnant and postpartum women[J]. Vaccines,2022,10(12):1-14.
|
[21] |
Kwok J, Hall HA, Murray AL, et al. The association between analgesic drug use in pregnancy and neurodevelopmental disorders: protocol for an umbrella review[J]. Systematic Reviews,2020,9(1):1-7.
|